
Kyowa Kirin is a Japanese pharmaceutical company with a global presence. It was established in 1953 through the merger of two companies, Kirin Seiyaku and Kyowa Hakko.
The company's business operations are divided into three main areas: pharmaceuticals, life sciences, and diagnostics. This structure allows Kyowa Kirin to focus on developing innovative treatments and diagnostic tools.
Kyowa Kirin's pharmaceutical business is its largest segment, accounting for over 70% of the company's revenue. This segment includes the development and marketing of prescription medications for various diseases and conditions.
Kyowa Kirin's product portfolio includes a range of prescription medications, including those for cancer, allergy, and autoimmune diseases.
Explore further: Includes Budget Authority Fund Allocation
History and Structure
Kyowa Kirin has a rich history that dates back to 1949 when its forerunner, Kyowa Hakko Kogyo Co., Ltd., was established.
The company has undergone significant changes over the years, with a major merger taking place in 2008 when it merged with Kirin Pharma Co., Ltd. to form Kyowa Hakko Kirin.

In 2014, the company acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million through its subsidiary ProStrakan Group.
In 2019, Kirin Holdings acquired a 95% stake in Kyowa Hakko Bio, the company's subsidiary corporation, and renamed it Kyowa Kirin Co., Ltd.
Kyowa Kirin has also been expanding its international presence, with plans to spin its established medicines portfolio into a new joint venture with German company GrĂ¼nenthal announced in November 2022.
For your interest: Adidas Subsidiary Companies
Manufacturing and Operations
Kyowa Kirin has a significant presence in the pharmaceutical manufacturing sector. The company operates multiple manufacturing facilities around the world.
In the United States, Kyowa Kirin has a pharmaceutical manufacturing facility in Princeton, New Jersey.
Additionally, the company has a facility in Galashiels, Selkirkshire, which is also involved in pharmaceutical manufacturing.
Kyowa Kirin's global reach extends to Japan, where it has a primary location in Otemachi Financial City Grand Cube in Tokyo. Getting directions to this location is a straightforward process.
Kyowa Kirin's manufacturing and operations are spread across several locations, including:
- Princeton, New Jersey (Pharmaceutical Manufacturing)
- Galashiels, Selkirkshire (Pharmaceutical Manufacturing)
- Otemachi Financial City Grand Cube, Tokyo (Primary Location)
Research and Development
Kyowa Kirin is actively developing and commercializing new products, including pipeline drugs. Their shifting product portfolios require careful analysis to stay ahead of the market.
Kyowa Kirin's pipeline drugs are a key area of focus for the company. To contend with their shifting product portfolios, it's essential to identify which of their products will be commercialized.
Kyowa Kirin's clinical trials provide valuable insights into their go-to-market proposition. This includes information on their clinical operations, recruitment, and trial strategy.
By understanding Kyowa Kirin's clinical trial strategy, you can gain a competitive edge in the market.
Readers also liked: Docusign Free Trial Limitations
Regulatory and Financial
Kyowa Kirin has a keen eye on regulatory milestones, tracking drug and patent expiries to stay ahead of the curve. This allows the company to prepare for potential changes in the market.
The company's focus on geographies impacted by these expiries is a testament to its commitment to understanding the complex landscape of the pharmaceutical industry.
Regulatory and Financial

You can track drug and patent expiries along with geographies impacted, which is crucial for businesses to stay ahead in the market.
Kyowa Kirin Co Ltd's catalyst impacts can be proactively evaluated to improve corporate planning and bolster business development with timely opportunities.
Businesses can use these tools to stay one step ahead of the competition and make informed decisions about investments and resource allocation.
By tracking regulatory milestones and catalyst impacts, companies can identify potential risks and opportunities, and adjust their strategies accordingly.
This information can help businesses to anticipate and prepare for changes in the market, reducing the risk of unexpected setbacks and increasing the chances of success.
Explore further: Scalable Creative Solutions Large Businesses
Net Income Growth
Net Income Growth is a crucial metric for any business, and it's essential to understand how it's affected by regulatory and financial factors.
Many companies struggle to grow their net income, but some have found success by adapting to changing market conditions.

If you're looking to boost your net income, it's worth considering the experiences of market leaders and start-ups who have achieved significant growth.
A few key takeaways from these companies include:
- Identifying new revenue streams to offset declining profits
- Optimizing operational costs to increase margins
- Investing in strategic partnerships to drive growth
- Adapting to changing regulatory environments to avoid costly compliance issues
By learning from these examples, you can develop a growth strategy that works for your business.
Updates and Events
Kyowa Kirin has a strong presence in the global pharmaceutical market, with a diverse portfolio of products that cater to various therapeutic areas.
The company's pipeline is focused on innovative treatments for diseases such as cancer, autoimmune disorders, and infectious diseases.
Kyowa Kirin's commitment to research and development is evident in its investment of over 20% of its sales in R&D.
The company has a global presence with operations in over 20 countries worldwide.
Kyowa Kirin has a long history of innovation, with the first approval of its product, "Anzemet", in 1997.
The company's mission is to contribute to the health and well-being of people around the world through the discovery and development of innovative medicines.
Competitive Analysis
Kyowa Kirin is one of the major players in the Japanese pharmaceutical industry. It has a significant presence in the market, with a large number of employees.
The company is headquartered in Chiyoda-Ku, Tokyo, and its entity type is public. This means that it is listed on a stock exchange and its financial information is publicly available.
Kyowa Kirin's headcount is 5,669 employees, which is relatively smaller compared to some of its competitors. For example, Takeda Pharmaceutical Co Ltd has a massive workforce of 47,455 employees.
Here's a comparison of the key parameters of Kyowa Kirin and its competitors:
Overall, Kyowa Kirin's size and market presence are significant, but it still lags behind some of its larger competitors.
Frequently Asked Questions
What drugs does Kyowa Kirin make?
Kyowa Kirin manufactures a range of biopharmaceuticals, including CRYSVITA (burosumab) and others listed here, which are used to treat various conditions. These medications are developed to address specific health needs and improve patient outcomes.
What kind of company is Kyowa Kirin?
Kyowa Kirin is a life sciences company specializing in biotechnology. It focuses on advancing life sciences and technologies to improve global health and well-being.
Featured Images: pexels.com


